OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Price, News & Analysis $0.0001 0.00 (-50.00%) As of 10:47 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Endonovo Therapeutics Stock (OTCMKTS:ENDV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Endonovo Therapeutics alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0016Volume175,065 shsAverage Volume31.44 million shsMarket Capitalization$120.66 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Read More Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENDV Stock News HeadlinesEndonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, IncMarch 28, 2024 | globenewswire.comEndonovo’s SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | finance.yahoo.comThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires in history, one tiny AI stock is flying under the radar. While you can't invest directly, we've pinpointed a stock poised to benefit immensely from his plans.September 4 at 2:00 AM | Behind the Markets (Ad)Endonovo's SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | globenewswire.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionDecember 4, 2023 | finance.yahoo.comEndonovo Therapeutics, Inc. (ENDV)November 21, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO)November 15, 2023 | investing.comEndonovo receives Taiwanese approval for SofPulse technologyOctober 13, 2023 | msn.comSee More Headlines ENDV Stock Analysis - Frequently Asked Questions How have ENDV shares performed this year? Endonovo Therapeutics' stock was trading at $0.0004 on January 1st, 2025. Since then, ENDV stock has decreased by 75.0% and is now trading at $0.0001. How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Novavax (NVAX), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Citigroup (C) and Ekso Bionics (EKSO). Company Calendar Today9/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ENDV CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$10 thousand Price / Sales12.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book0.00Miscellaneous Outstanding Shares1,206,610,000Free Float1,138,923,000Market Cap$120.66 thousand OptionableNot Optionable Beta-1.39 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:ENDV) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.